Is ELAB or ENGN more undervalued in 2026?

CirclFi compares PMGC Holdings Inc. (ELAB) and enGene Therapeutics Inc. (ENGN) using 13 institutional-grade valuation models. ELAB has a Quality of Company score of 4.4/10 while ENGN scores 4.1/10.

Which is a better buy — ELAB or ENGN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ELAB and ENGN valuations compare?

ELAB at $1.92 and ENGN at $1.78 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ELAB vs ENGN Valuation Comparison 2026 — Intrinsic Value Analysis

ELAB

Biotechnology

PMGC Holdings Inc.

Quality

4.4

out of 10

Value Trap

LOW

Price

$1.92

Last close

Models

11/13

Active

ENGN

Biotechnology

enGene Therapeutics Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$1.78

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	ELAB Fair Value	ELAB Upside	ENGN Fair Value	ENGN Upside
Bayesian DCF	Intrinsic	$2.08	+8.1%	$0.58	-67.6%
Earnings Power Value	Intrinsic	$1.32	-47.4%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.49	-22.2%	$1.92	+8.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ELAB vs ENGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ELAB vs ENGN — Which Stock Is More Undervalued?

ELAB scores higher with a 4.4/10 quality rating vs ENGN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing PMGC Holdings Inc. (ELAB) and enGene Therapeutics Inc. (ENGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ELAB currently trades at $1.92 with a QOC of 4.4/10, while ENGN trades at $1.78 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).